FDOPA
Adult Oligodendroglioma
Erik MittraSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Oligodendroglioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus National Cancer Institute (NCI) | Phase 1/2 | CCC |
Plerixafor Lawrence Recht | Phase 1/2 | CCC |
Perifosine National Cancer Institute (NCI) | Phase 1/2 | CCC |
Alisertib Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 | CC |
Isotretinoin Wake Forest University Health Sciences | Phase 1 | CC |
View all 10 →
Same molecule, other indications
FDOPA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →